Cargando…
Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion
The arachidonic acid pathway participates in immunosuppression in various types of cancer. Our previous observation detailed that microsomal prostaglandin E2 synthase 1 (mPGES-1), an enzyme downstream of cyclooxygenase 2 (COX-2), limited antitumor immunity in melanoma; in addition, genetic depletion...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389052/ https://www.ncbi.nlm.nih.gov/pubmed/37529399 http://dx.doi.org/10.1158/2767-9764.CRC-23-0210 |
_version_ | 1785082213874794496 |
---|---|
author | Fukuda, Yasunari Kim, Sun-Hee Bustos, Matias A. Cho, Sung-Nam Roszik, Jason Burks, Jared K. Kim, Hong Hoon, Dave S.B. Grimm, Elizabeth A. Ekmekcioglu, Suhendan |
author_facet | Fukuda, Yasunari Kim, Sun-Hee Bustos, Matias A. Cho, Sung-Nam Roszik, Jason Burks, Jared K. Kim, Hong Hoon, Dave S.B. Grimm, Elizabeth A. Ekmekcioglu, Suhendan |
author_sort | Fukuda, Yasunari |
collection | PubMed |
description | The arachidonic acid pathway participates in immunosuppression in various types of cancer. Our previous observation detailed that microsomal prostaglandin E2 synthase 1 (mPGES-1), an enzyme downstream of cyclooxygenase 2 (COX-2), limited antitumor immunity in melanoma; in addition, genetic depletion of mPGES-1 specifically enhanced immune checkpoint blockade therapy. The current study set out to distinguish the roles of mPGES-1 from those of COX-2 in tumor immunity and determine the potential of mPGES-1 inhibitors for reinforcing immunotherapy in melanoma. Genetic deletion of mPGES-1 showed different profiles of prostaglandin metabolites from that of COX-2 deletion. In our syngeneic mouse model, mPGES-1–deficient cells exhibited similar tumorigenicity to that of COX-2–deficient cells, despite a lower ability to suppress PGE2 synthesis by mPGES-1 depletion, indicating the presence of factors other than PGE2 that are likely to regulate tumor immunity. RNA-sequencing analysis revealed that mPGES-1 depletion reduced the expressions of collagen-related genes, which have been found to be associated with immunosuppressive signatures. In our mouse model, collagen was reduced in mPGES-1–deficient tumors, and phenotypic analysis of tumor-infiltrating lymphocytes indicated that mPGES-1–deficient tumors had fewer TIM3(+) exhausted CD8(+) T cells compared with COX-2–deficient tumors. CAY10678, an mPGES-1 inhibitor, was equivalent to celecoxib, a selective COX-2 inhibitor, in reinforcing anti-PD-1 treatment. Our study indicates that mPGES-1 inhibitors represent a promising adjuvant for immunotherapies in melanoma by reducing collagen deposition and T-cell exhaustion. SIGNIFICANCE: Collagen is a predominant component of the extracellular matrix that may influence the tumor immune microenvironment for cancer progression. We present here that mPGES-1 has specific roles in regulating tumor immunity, associated with several collagen-related genes and propose that pharmacologic inhibition of mPGES-1 may hold therapeutic promise for improving immune checkpoint–based therapies. |
format | Online Article Text |
id | pubmed-10389052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-103890522023-08-01 Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion Fukuda, Yasunari Kim, Sun-Hee Bustos, Matias A. Cho, Sung-Nam Roszik, Jason Burks, Jared K. Kim, Hong Hoon, Dave S.B. Grimm, Elizabeth A. Ekmekcioglu, Suhendan Cancer Res Commun Research Article The arachidonic acid pathway participates in immunosuppression in various types of cancer. Our previous observation detailed that microsomal prostaglandin E2 synthase 1 (mPGES-1), an enzyme downstream of cyclooxygenase 2 (COX-2), limited antitumor immunity in melanoma; in addition, genetic depletion of mPGES-1 specifically enhanced immune checkpoint blockade therapy. The current study set out to distinguish the roles of mPGES-1 from those of COX-2 in tumor immunity and determine the potential of mPGES-1 inhibitors for reinforcing immunotherapy in melanoma. Genetic deletion of mPGES-1 showed different profiles of prostaglandin metabolites from that of COX-2 deletion. In our syngeneic mouse model, mPGES-1–deficient cells exhibited similar tumorigenicity to that of COX-2–deficient cells, despite a lower ability to suppress PGE2 synthesis by mPGES-1 depletion, indicating the presence of factors other than PGE2 that are likely to regulate tumor immunity. RNA-sequencing analysis revealed that mPGES-1 depletion reduced the expressions of collagen-related genes, which have been found to be associated with immunosuppressive signatures. In our mouse model, collagen was reduced in mPGES-1–deficient tumors, and phenotypic analysis of tumor-infiltrating lymphocytes indicated that mPGES-1–deficient tumors had fewer TIM3(+) exhausted CD8(+) T cells compared with COX-2–deficient tumors. CAY10678, an mPGES-1 inhibitor, was equivalent to celecoxib, a selective COX-2 inhibitor, in reinforcing anti-PD-1 treatment. Our study indicates that mPGES-1 inhibitors represent a promising adjuvant for immunotherapies in melanoma by reducing collagen deposition and T-cell exhaustion. SIGNIFICANCE: Collagen is a predominant component of the extracellular matrix that may influence the tumor immune microenvironment for cancer progression. We present here that mPGES-1 has specific roles in regulating tumor immunity, associated with several collagen-related genes and propose that pharmacologic inhibition of mPGES-1 may hold therapeutic promise for improving immune checkpoint–based therapies. American Association for Cancer Research 2023-07-31 /pmc/articles/PMC10389052/ /pubmed/37529399 http://dx.doi.org/10.1158/2767-9764.CRC-23-0210 Text en © 2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. |
spellingShingle | Research Article Fukuda, Yasunari Kim, Sun-Hee Bustos, Matias A. Cho, Sung-Nam Roszik, Jason Burks, Jared K. Kim, Hong Hoon, Dave S.B. Grimm, Elizabeth A. Ekmekcioglu, Suhendan Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion |
title | Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion |
title_full | Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion |
title_fullStr | Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion |
title_full_unstemmed | Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion |
title_short | Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion |
title_sort | inhibition of microsomal prostaglandin e2 synthase reduces collagen deposition in melanoma tumors and may improve immunotherapy efficacy by reducing t-cell exhaustion |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389052/ https://www.ncbi.nlm.nih.gov/pubmed/37529399 http://dx.doi.org/10.1158/2767-9764.CRC-23-0210 |
work_keys_str_mv | AT fukudayasunari inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion AT kimsunhee inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion AT bustosmatiasa inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion AT chosungnam inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion AT roszikjason inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion AT burksjaredk inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion AT kimhong inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion AT hoondavesb inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion AT grimmelizabetha inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion AT ekmekcioglusuhendan inhibitionofmicrosomalprostaglandine2synthasereducescollagendepositioninmelanomatumorsandmayimproveimmunotherapyefficacybyreducingtcellexhaustion |